HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer—A study of two hundred cases

Sáez, Amparo; Andreu, Francisco Javier; Seguí, M. Á.; Baré, Marisa; Fernández, Sara; Dinarès, Carme; Rey, M.

doi:10.1016/j.breast.2005.09.008

Cited by 58 publications

(58 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CISH combines the chromogenic signal detection method of immunohistochemistry techniques with in situ hybridization [31]. This procedure was developed as an alternative to FISH for the detection of HER-2/neu oncogene amplification [31].…”

Section: Cytogenetic Analysismentioning

confidence: 99%

Lymph Node Fine-Needle Cytology: Beyond Flow Cytometry

Peluso

Ieni²,

Mignogna³

et al. 2016

Acta Cytologica

View full text Add to dashboard Cite

Lymph node (LN) fine-needle cytology (FNC) coupled with flow cytometry immunophenotyping provides relevant information for the diagnosis of non-Hodgkin lymphoma (NHL). Numerous studies have shown FNC samples to be suitable for different molecular procedures; in this review, some of the molecular procedures most commonly employed for NHL are briefly described and evaluated in this perspective. Fluorescence in situ hybridization and chromogenic in situ hybridization are briefly described. Polymerase chain reaction (PCR)-based assays are used to identify and quantify mutations and translocations, namely immunoglobulin (IGH) and T-cell receptor rearrangements by clonality testing and IGVH somatic hypermutations either by Sanger sequencing, single-strand conformational polymorphisms or RT-PCR strategies. High-throughput technologies (HTT) encompass numerous and different diagnostic tools that share the capacity of multiple molecular investigation and sample processing in a fast and reproducible manner. HTT includes gene expression profiling, comparative genomic hybridization, single-nucleotide polymorphism arrays and next-generation sequencing technologies. A brief description of these tools and their potential application to LN FNC is reported. The challenge for FNC will be to achieve new knowledge and apply new technologies to FNC, exploiting its own basic qualities.

show abstract

Section: Cytogenetic Analysismentioning

confidence: 99%

Lymph Node Fine-Needle Cytology: Beyond Flow Cytometry

Peluso

Ieni²,

Mignogna³

et al. 2016

Acta Cytologica

View full text Add to dashboard Cite

show abstract

“…0% for Cerb B2 IHC (1+) in the studies [20][21][22][23][24][25]27]. The percentage of FISH negativity ranged from 6.2% to 23.5% for Cerb B2 IHC(3+) cases [20][21][22][23][24][25]27]. Therefore we consider that, direct FISH test is proper for all cases with breast cancer when evaluating Cerb B2 receptor status.…”

Section: Resultsmentioning

confidence: 84%

“…The percentage of positive FISH results (median) was 3.5 for IHC(0), 5.9 for IHC (1+), 17.6 for IHC (2+), and 83.5 for IHC (3+) [26]. The percentage of positive FISH results for IHC (2+) cases were found to be 16.9%, 6.7%, 92.3%, 25.7% and 16.9% in the studies [20][21][22][23][24][25]. In our study, percentage of positive FISH cases was 43.5%.…”

Section: Resultsmentioning

confidence: 89%

Should FISH Test be Performed to all Patients With Breast Cancer?

Mutlu¹,

Karaca²,

Akca³

et al. 2013

Med-Science

View full text Add to dashboard Cite

CerbB2 receptor determination is very important for the prognosis and treatment of breast cancer. The most used two methods for CerbB2 receptor determination are immunohistochemistry and FISH methods. FISH method is recommended for immunohistochemically CerbB2 (++) patient group. Therefore, even though the immunohistochemically CerbB2 (++) patients are in the same group, FISH test divides the results into two separate groups. Our study compared these two groups in terms of relaps duration. Total of 85 patients from The Kayseri Research and Training Hospital in Kayseri, Kayseri Erciyes University Hospital and Mersin State Hospital were included in this study. The relaps duration of the patients were determined and then compared statistically. When the mean disease free survival was compared for FISH(+) and FISH(−) groups, the mean DFS was 46±5 and 73±8 months. However, the median DFS was 38±9 months for the FISH positive group. No median PFS was reached for FISH (−) group. Immunohistochemically CerbB2 (++) breast cancer patients are considered as in the same group, however actually they have different prognostic features. Similarly, when the immunohistochemical tests and FISH tests are compared for CerbB2 positivity, different results are obtained. As a consequence of that, the therapy alternatives will be changed. Therefore, we conclude that the FISH test should be performed to all patients.

show abstract

“…11 The conventional FISH technique on histology samples requires 2 days because of overnight hybridization of the probes. The new IQFISH method was developed to shorten the procedure and allow a 1-day application requiring only 1.5 to 2 hours for proper probe binding.…”

Section: Discussionmentioning

confidence: 99%

One-Day FISH Approach for the High-Speed Determination of HER2 Gene Copy Status in Breast Carcinoma

Hegyi

Lønborg

Mónus

et al. 2013

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Fluorescence in situ hybridization (FISH) is a commonly used method to detect chromosomal aberrations, for example, to assess human epidermal growth factor receptor 2 (HER2) gene status in breast carcinoma. The classical FISH approach requires overnight incubation for proper hybridization result. Tissue morphologic features are varying because of aggressive pretreatment and application of high temperatures. To eliminate some of the methodological problems, a new 1-day FISH method was recently introduced. The aim of our study was to evaluate the utility of the Instant Quality FISH with the conventional FISH kit from the same provider (Dako pharmDx) for determination of HER2 status.We performed in situ hybridization on the same 40 invasive breast carcinoma samples with both probe kits, and HER2/ CEN17 and chromosome 17/cell nucleus ratios were calculated. FISH signal stability was also tested by the reassessment of the slides after 2 months storage. The accordance regarding HER2 gene amplification status between the 2 FISH kits tested was 100%. There was an excellent correlation between HER2/ CEN17 ratios with a concordance correlation coefficient of 0.958 and correlation coefficient (R) of 0.959. The 1-day HER2 Instant Quality FISH diagnostic kit points with fast and stable reaction showing the same result in the diagnostic practice when compared with the conventional overnight FISH method.Key Words: HER2, IQFISH, FISH, breast cancer, high-speed FISH (Appl Immunohistochem Mol Morphol 2013;00:000-000) T he human epidermal growth factor receptor 2 (HER2, c-erbB-2) gene localizes at 17q21 and encodes a transmembrane tyrosine kinase receptor protein that is involved in the process of cell growth. 1 Amplification of HER2 gene AQ4 occurs in 15% to 25% of invasive breast cancers. 2 The gene amplification is associated with overexpression of the HER2 protein, a feature with strong prognostic impact for increased risk of recurrence and short survival. 3 As the HER2 status predicts therapeutic response to cyclosporamide, methotrexate fluorouracil, 4 and trastuzumab 5,6 as well, the accurate determination of the gene status has great clinical significance.In situ hybridization is a powerful molecular genetic technique allowing the assessment of gene copy numbers by microscopic visualization in interphase nuclei in formaldehyde-fixed and paraffin-embedded sections and tissue microarray samples. 7 Fluorescence in situ hybridization (FISH) is a commonly used method for determining HER2 gene amplification status in breast cancer. 8 Unfortunately, the conventional FISH method performed on histologic specimens is rather time consuming as an overnight incubation is required for proper probe annealing and target DNA hybridization. 9 Moreover, tissue integrity is sometimes influenced by aggressive pretreatment and hybridization reagents. To overcome these problems, a modified FISH method was recently introduced, which requires only 1.5 to 2 hours of hybridization time; thanks to the adjustment of the hybridization buffer a...

show abstract

HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer—A study of two hundred cases

Cited by 58 publications

References 37 publications

Lymph Node Fine-Needle Cytology: Beyond Flow Cytometry

Lymph Node Fine-Needle Cytology: Beyond Flow Cytometry

Should FISH Test be Performed to all Patients With Breast Cancer?

One-Day FISH Approach for the High-Speed Determination of HER2 Gene Copy Status in Breast Carcinoma

Contact Info

Product

Resources

About